NEWS

Nobio gets FDA approval for anti-bacterial dental fillings

August 5, 2019

TEL AVIV (Reuters) – Israel’s Nobio Ltd said on Monday it received approval from the U.S. Food and Drug Administration to market its anti-bacterial composite designed to remain in the teeth for decades.

Read More

Can This Ancient Greek Medicine Cure Humanity?

July 26, 2019

There’s fresh interest in a fabled shrub on the Aegean island of Chios.

Read More

Marius Nacht Buys Controlling Stake in Universal Flu Vaccine Developer BiondVax

July 17, 2019

Based in Jerusalem, Nasdaq-listed BiondVax develops a universal flu vaccine, currently in advanced clinical trials

Read More

First Participant Enrolled in Second Cohort of BiondVax’s Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial

July 8, 2019

BiondVax’s M-001 universal flu vaccine candidate is designed to improve upon currently marketed strain-specific vaccines in several ways.

Read More

ArcherDX and Ayala Pharmaceuticals Announce Strategic Companion Diagnostic Collaboration

July 8, 2019

Enabling Genomically Defined Treatments for Underserved Cancers

Read More

AI triage solution for brain bleeds gains FDA clearance

June 17, 2019

Zebra Medical Vision announced Monday, June 17, that its AI solution for intracranial hemorrhage (ICH) alerts has gained FDA approval.

Read More

CartiHeal Enrolls the 200th Patient in Its Pivotal Clinical Study in San Diego, CA

June 12, 2019

CartiHeal is the developer of the Agili-C™ implant for treating cartilage and osteochondral defects in traumatic and osteoarthritic joints,

Read More

Ayala Pharmaceuticals Raises $30 Million

May 29, 2019

The Israel-based company intends to use the new round of funding to advance the clinical development of its anti-cancer product

Read More

FDA Grants Theranica De Novo to Market First Smartphone-controlled Acute Migraine-relief Wearable Device

May 28, 2019

Clinical Data Show 66.7% Pain Relief Response Within Two Hours

Read More

Model of personalized postprandial glycemic response to food developed for an Israeli cohort predicts responses in Midwestern American individuals.

May 16, 2019

Research paper published in the American Journal of Clinical Nutrition

Read More

Gains in tRNAslation: It’s time for investors to realize the potential of European RNA technologies

November 2, 2020

Dr. Gur Roshwalb, aMoon Managing Director, discusses how investing in new innovative RNA technologies can lead to rapid value creation, and why Europe is a fertile ground to hunt for them.

Read More

Remote electric neuromodulation device approval extended to treatment of chronic migraine

October 27, 2020

The Food and Drug Administration (FDA) has expanded the approval of Nerivio® (Theranica) to include acute treatment of migraine with or without aura in patients aged 18 years and older with chronic migraine. Previously, the device had only been approved in those with episodic migraine.

Read More

Combining machine learning tools for medical imaging with genetic sequencing nets Sophia Genetics $110M

October 1, 2020

With the closure of its sixth venture capital round, the Swiss health data firm Sophia Genetics added another $110 million to its coffers in a series F financing led by aMoon and Hitachi Ventures.

Read More

Venture capitalists find more to Israel than Zionism

September 30, 2020

Not all olim arrive in Israel to serve in the IDF or go to university. In the case of two aMoon executives, coming to Israel was a way to advance their careers in venture capital health investments while also reaching the goal of living in the Jewish state.

Read More

Alexa, do I have COVID-19?

September 30, 2020

In March, as the staggering scope of the pandemic started to become clear, officials around the world began enlisting the public to join in the fight. In Israel, the defense ministry and a start-up company called Vocalis Health asked people to donate their voices.

Read More

Adicet Announces Completion of Merger with resTORbio

September 15, 2020

Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the completion of its previously announced merger with resTORbio, Inc

Read More

Seer Announces Spin Out of PrognomIQ with $55 Million Initial Financing

September 15, 2020

Seer, Inc., an aMoon2 portfolio company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and scalable proteomics information, today announced that it has spun out and completed the initial financing of $55M for a newly formed healthcare company, PrognomIQ, Inc.

Read More

MiNA Therapeutics Secures £23 Million Series A Financing to Advance First-in-Class Activating RNA-Based Therapeutics

September 10, 2020

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the completion of a £23 million ($30 million) Series A equity financing led by aMoon, Israel’s largest healthtech and life sciences venture fund.

Read More

MOBILion Closes $35M Series B Financing Round

August 17, 2020

aMoon leads round to expand product portfolio and advance commercial efforts for MOBILion’s SLIM technology for biotherapeutics characterization and novel biomarker discovery

Read More

Roche invests millions in Israel’s health tech sector

August 11, 2020

has entered into a partnership agreement with aMoon, an Israeli venture capital company focused on health technology and science. The “StarFinder Lab” collaboration is aiming to help young startups develop innovative diagnostic tools to tackle global health care challenges.

Read More